Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C70H105FN20O23 |
| Molecular Weight | 1612.7038 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC([18F])C(=O)NCCOCCOCCOCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H]1NC(=O)[C@@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O)C(=O)NCCCC[C@@H]3NC(=O)[C@@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC3=O
InChI
InChIKey=YAOQNDCEKABEDO-RTOYRMACSA-N
InChI=1S/C70H105FN20O23/c1-39(71)59(102)78-26-27-112-28-29-113-30-31-114-38-56(97)83-48(60(103)77-23-5-3-9-47-64(107)87-45(11-7-25-80-70(74)75)62(105)82-37-55(96)85-52(35-58(100)101)68(111)91-50(66(109)89-47)33-41-14-18-43(93)19-15-41)20-21-53(94)76-22-4-2-8-46-63(106)86-44(10-6-24-79-69(72)73)61(104)81-36-54(95)84-51(34-57(98)99)67(110)90-49(65(108)88-46)32-40-12-16-42(92)17-13-40/h12-19,39,44-52,92-93H,2-11,20-38H2,1H3,(H,76,94)(H,77,103)(H,78,102)(H,81,104)(H,82,105)(H,83,97)(H,84,95)(H,85,96)(H,86,106)(H,87,107)(H,88,108)(H,89,109)(H,90,110)(H,91,111)(H,98,99)(H,100,101)(H4,72,73,79)(H4,74,75,80)/t39?,44-,45-,46-,47-,48-,49+,50+,51-,52-/m0/s1/i71-1
| Molecular Formula | C70H105FN20O23 |
| Molecular Weight | 1612.7038 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 10 |
| E/Z Centers | 4 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:27:37 GMT 2025
by
admin
on
Tue Apr 01 16:27:37 GMT 2025
|
| Record UNII |
E8XU52J025
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
E8XU52J025
Created by
admin on Tue Apr 01 16:27:37 GMT 2025 , Edited by admin on Tue Apr 01 16:27:37 GMT 2025
|
PRIMARY | |||
|
1346416-53-2
Created by
admin on Tue Apr 01 16:27:37 GMT 2025 , Edited by admin on Tue Apr 01 16:27:37 GMT 2025
|
PRIMARY | |||
|
134823891
Created by
admin on Tue Apr 01 16:27:37 GMT 2025 , Edited by admin on Tue Apr 01 16:27:37 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
The administration of 18F-FPPRGD2 was well tolerated, with no marked effects on vital signs, ECG readings, or laboratory values. The tracer showed the same pattern of biodistribution in all volunteers: primary clearance through the kidneys (0.360 rem/mCi +/- 0.185 (0.098 mSv/MBq +/- 0.050)) and bladder (0.862 rem/mCi +/- 0.436 (0.233 mSv/MBq +/- 0.118), voiding model) and uptake in the spleen (0.250 rem/mCi +/- 0.168 (0.068 mSv/MBq +/- 0.046)) and large intestine (0.529 rem/mCi +/- 0.236 (0.143 mSv/MBq +/- 0.064)). The mean effective dose of 18F-FPPRGD2 was 0.1462 rem/mCi +/- 0.0669 (0.0396 mSv/MBq +/- 0.0181). With an injected dose of 10 mCi (370 MBq) and a 1-hour voiding interval, a patient would be exposed to an effective radiation dose of 1.5 rem (15 mSv). Above the diaphragm, there was minimal uptake in the brain ventricles, salivary glands, and thyroid gland. Time-activity curves showed rapid clearance from the vasculature, with a mean 26% +/- 17 of the tracer remaining in the circulation at 30 minutes and most of the activity occurring in the plasma relative to cells (mean whole bloodplasma ratio, 0.799 +/- 0.096).
|
||
|
ACTIVE MOIETY |
Official Title: Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of .ALPHA.v.BETA.3 Integrins Expression as a Biomarker of Angiogenesis
Purpose: The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. We will assess the uptake of this novel radiopharmaceutical in subjects with breast cancer, lung cancer, glioblastoma multiforme (GBM) and other cancers requiring antiangiogenesis treatment.
|
